Dr. Rodrigo A. Toledo - Dra. Elena Élez
VIEW MORE
Published in Nature Medicine, a VHIO-led study has unveiled a new predictive biomarker of response to anti-BRAF/EGFR combinatory therapy in...
VHIO-led study unveils predictive biomarker of response to therapy in patients with microsatellite stable BRAFV600E metastatic colorectal cancer
Proyecto UNCAN.eu
VIEW MORE
The Coordination and Support Action “4.UNCAN.eu” had its official kick-off on September 8-9 2022 with a public event hosted by...
UNCAN.eu: a European initiative to better understand cancer
Dr. Jaume Capdevila
VIEW MORE
Results of the DUTHY exploratory phase II study evaluating dual immune checkpoint blockade with durvalumab and tremelimumab show promising activity...
ESMO Congress 2022: VHIO co-led studies point to a potential new therapeutic strategy and treatment sequence for advanced neuroendocrine tumors

Latest News

Published in Nature Medicine, a VHIO-led study has unveiled a new predictive biomarker of response to anti-BRAF/EGFR combinatory therapy in…

+

The Coordination and Support Action “4.UNCAN.eu” had its official kick-off on September 8-9 2022 with a public event hosted by…

+

Research Programs

PRECLINICAL & TRANSLATIONAL RESEARCH
Cellular Plasticity and Cancer Group

Our group focuses on the interplay between cellular plasticity, stem cells and cancer. Cellular plasticity is recognized today as a critical feature of cancer cells that enables them to transit between different cellular states, including reversible transitions.

Cellular Plasticity and Cancer Group
PRECLINICAL & TRANSLATIONAL RESEARCH
Growth Factors Group

We focus our research on mechanisms of resistance to targeted therapies and most importantly, how to overcome it by showing that breast cancers resistant to T-DM1, an antibody-drug conjugate ADC)- can be efficiently treated with the second generation ADC SYD985 (Nadal-Serrano et al.).

Growth Factors Group
CORE TECHNOLOGIES
Cancer Genomics Group

VHIO’s Cancer Genomics Group serves as a Core Technology laboratory. We are also dedicated to translational research as well as the development of novel genomic tests.

Cancer Genomics Group

PRINCIPAL RESEARCHERS

Alena Gros
Alena Gros
Tumor Immunology and Immunotherapy Group

Our group focuses on better understanding the naturally occurring T-cell response to cancer and establishing ways to exploit these antitumor…

JUDIT_BALMAÑA
Judith Balmaña
Hereditary Cancer Genetics Group

We focus on the clinical development of PARP inhibitors (PARPi) in early gBRCA1/2 breast cancer, and novel combinations in the…

TERESA
Teresa Macarulla
Gastrointestinal and Endocrine Tumors Group

Our group continues to play an essential role in developing molecular therapies against GI malignancies. We make important contributions to…

Elena_Garralda
Elena Garralda
Early Clinical Drug Development Group

We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and…

Events

Tuesday 4 October 22 - 10:30 AM scientific-seminars Francisco Martínez-Jimenez I Understanding tumor evolution and its interplay with the immune system
Thursday 13 October 22 - 11:00 AM Patients Surgery and breast cancer: when, how and on which patients can it be performed?
Friday 14 October 22 - 12:00 PM scientific-seminars Alejo Efeyan I The nutrient – Rag GTPase signaling as a driver of cancer and aging
Monday 24 October 22 - 12:00 PM scientific-seminars Mate Maus | TBC